J
John Q. Trojanowski
Researcher at University of Pennsylvania
Publications - 1538
Citations - 245534
John Q. Trojanowski is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 226, co-authored 1467 publications receiving 213948 citations. Previous affiliations of John Q. Trojanowski include Vanderbilt University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
William T. Hu,Kelly D. Watts,Leslie M. Shaw,Jennifer C. Howell,John Q. Trojanowski,Sundeep Basra,Jonathan D. Glass,James J. Lah,Allan I. Levey +8 more
TL;DR: To characterize biological and technical factors which influence cerebrospinal fluid (CSF) biomarker levels, including the presence of apolipoprotein E (APOE) ε4 allele, AD diagnosis, Aβ‐binding proteins, sample processing, and preanalytical handling.
Journal ArticleDOI
Longitudinal progression of grey matter atrophy in non-amnestic Alzheimer’s disease
Jeffrey S. Phillips,Fulvio Da Re,Fulvio Da Re,David J. Irwin,Corey T. McMillan,Sanjeev N. Vaishnavi,Sharon X. Xie,Edward B. Lee,Philip A. Cook,James C. Gee,Leslie M. Shaw,John Q. Trojanowski,David A. Wolk,Murray Grossman +13 more
TL;DR: Medial temporal sparing in non-amnestic Alzheimer's disease may be due in part to later onset of medial temporal degeneration than in amnestic patients rather than different rates of atrophy over time, and indirect support for the role of long-distance fibre pathways in the spread of neurodegenerative disease is provided.
Journal ArticleDOI
Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease.
Nicholas Lim,Christine R. Swanson,Hua‐Ren Cherng,Travis L. Unger,Sharon X. Xie,Daniel Weintraub,Ken Marek,Matthew B. Stern,Andrew Siderowf,John Q. Trojanowski,Alice Chen-Plotkin +10 more
TL;DR: This work investigates EGF as a predictive biomarker in prodromal PD, as well as AD, and nominates plasma epidermal growth factor as a biomarker predicting cognitive decline in patients with established PD.
Journal ArticleDOI
Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions
Michael P. Hart,Johannes Brettschneider,Virginia M.-Y. Lee,John Q. Trojanowski,Aaron D. Gitler +4 more
TL;DR: The paucity of large round TDP-43 inclusions in ALS cases with or without ataxin 2 intermediate-length polyQ expansions suggests a distinct pathological subtype of ALS and highlights the possibility for distinct pathogenic mechanisms.
Journal ArticleDOI
"Emerging Alzheimer's disease therapies: focusing on the future".
TL;DR: The Center for Neurodegenerative Disease Research (CNDR) organized a 1 day symposium entitled "Emerging Alzheimer's disease Therapies: Focusing On The Future" on November 7th, 2001 at the University of Pennsylvania in Philadelphia, PA, which focused on novel therapies for AD designed to prevent/eliminate Abeta deposits in the brains of AD patients.